GRI ▼ -4.5% - GRI Bio, Inc. $GRI - GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars GRI Bio shares fell 4.5% today following the company's presentation of Phase 2a data for GRI-0621 at the European Respiratory Society conference, which outlined the drug candidate's mechanism of action in idiopathic pulmonary fibrosis across nine mechanistic pathways. The market's negative reaction suggests investors may have viewed the data presentation as insufficient to support near-term clinical or commercial expectations, despite the detailed mechanistic findings disclosed. 08-SEP-2026 08:15 AM ET